AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY25 results · Jan–Mar 2025
AstraZeneca Pharma India reported revenue from operations of ₹480.48 crore (up 25.4% from Q4 FY24) and net profit of ₹58.25 crore (up 47.6% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a standalone basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 480.48 | 383.20 | +25.4% | 440.29 | +9.1% |
| Other income | 16.15 | 8.66 | +86.4% | 7.98 | +102.3% |
| Total income | 496.63 | 391.86 | +26.7% | 448.27 | +10.8% |
| Profit before tax | 78.47 | 54.35 | +44.4% | 42.02 | +86.7% |
| Net profit for the period | 58.25 | 39.48 | +47.6% | 30.85 | +88.8% |
| EPS, basic (₹) | 23.30 | 15.79 | +47.6% | 12.34 | +88.8% |
| Net margin (%) | 12.1 | 10.3 | 7.0 |
Standalone
- Filed with BSE
- 30 May 2025, 20:14 IST
- Board meeting
- 30 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE